1451-84-9

Basic information

• Product Name: 2-bromo-2-methylpropiophenone
• Synonyms: 2-bromo-1-(2-methylphenyl)propan-1-one;2-Bromo-1-o-tolylpropan-1-one
• CAS NO: 1451-84-9
• Molecular Formula: C₁₀H₁₁BrO
• Molecular Weight: 227.11
• Mol File: 1451-84-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 137-138 °C(Press: 12 Torr)
• Appearance: /
• Density: 1.357±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-bromo-2-methylpropiophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-2-methylpropiophenone(1451-84-9)
• EPA Substance Registry System: 2-bromo-2-methylpropiophenone(1451-84-9)

Safety Data

• Hazardous Substances Data: 1451-84-9(Hazardous Substances Data)

Usage

General Description

2-bromo-2-methylpropiophenone, also known as Bmk glycidate, is a synthetic chemical compound commonly used in the production of illegal drugs such as methamphetamine and MDMA. This chemical is a precursor for the synthesis of methylamphetamine and cathinone derivatives. It is a white crystalline solid at room temperature, and its chemical formula is C10H11BrO2. Due to its use in illegal drug production, 2-bromo-2-methylpropiophenone is a controlled substance and is regulated in many countries. However, it can be obtained through illicit channels and has been associated with illegal drug manufacturing operations.

Upstream product

• 1117-96-0 Diazoethan 
• 933-88-0 ortho-toluoyl chloride 
• 2040-14-4 2-methylpropiophenone 
• 95-46-5 2-methylphenyl bromide 
• 61017-92-3 1-(2-methylphenyl)-1-propanol 
• 74-96-4 ethyl bromide 
• 10108-64-2 cadmium(II) chloride 
• 529-20-4 2-methylphenyl aldehyde 

Downstream Products

• 16942-68-0 5-methyl-4-o-tolyl-thiazol-2-ylamine 
• 25412-56-0 1-o-Tolyl-propane-1,2-dione 

Relevant articles and documents

NBS-mediated synthesis of β-keto sulfones from benzyl alcohols and sodium arenesulfinates

An efficient synthetic route towards the synthesis of β-keto sulfones has been developed from secondary benzyl alcohols using N-bromosuccinimide (NBS). The present protocol utilizes NBS as oxidant as well as brominating agent, readily accessible benzyl alcohols and sodium arenesulfinates as the sulfonylating reagent under mild conditions. The control experiments revealed that the reaction proceeds via oxidation of alcohol to ketone, α-bromination of ketone and nucleophilic substitution by sodium arenesulfinate. Furthermore, the efficiency of the methodology was tested with a gram scale reaction and also shown the synthetic utility.

Diminished reactivity of ortho-substituted phenacyl bromides toward nucleophilic displacement

A systematic increase of substitution rates by tert-butylamine on α-bromopropiophenones is observed with meta or para substituents with increasing electron-withdrawing ability (k x 103 L M-1 min-1 = 12.7 (p-CH3), 15.7 (o-F), 20.5 (H), 20.0 (p-Cl), 23.6 (m-Cl), 27.3 (p-CF3)). Within an ortho-substituted series, the reactivities decrease (k x 103 L M-1 min-1 = 7.64 (o-OCH3), 5.31 (o-CH3), 2.85 (o-Cl), 2.40 (o-CF3)). Ortho-substitution results occur from rotational barrier effects and an Aδσ + Bδσ + repulsion. The major bonding contribution between reaction and α-substituent centers (A-B) is only the σ bond. When π bonding is allowed between A and B (meta/para-substitution), delocalization and stabilization of the reacting center occurs.

Pyrrole derivatives and medicinal composition

The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. STR1 (wherein R1 represents hydrogen or alkoxycar91 bonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted). The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.